Primary Mediastinal B-cell Lymphoma (PMBCL)
from OrphaChat — a Rare Disease Podcast Hosted by RCH
These sources examine the biological characteristics and evolving management of primary mediastinal B-cell lymphoma (PMBCL) and related aggressive malignancies. The texts highlight the Janus kinase/signal transducers (JAK-STAT) and NF-κB pathways as central drivers of the disease, which distinguish it from other lymphoma subtypes. Current frontline strategies focus on dose-adjusted EPOCH-R and R-CHOP regimens, often utilizing PET-CT scans to determine the necessity of consolidative radiotherapy. For patients with relapsed or refractory disease, emerging research evaluates the high efficacy of CAR T-cell therapy and immune checkpoint inhibitors like pembrolizumab. Furthermore, the literature introduces bispecific monoclonal antibodies, such as glofitamab and epcoritamab, as breakthrough options that redirect T-cells to target malignant cells. Ultimately, the collection emphasizes the shift towards precision medicine and targeted immunotherapies to improve outcomes for patients who fail traditional treatments.
Embed this episode
No transcript yet.